JP2006508332A - 前立腺癌検出改善のための血清中前立腺特異抗原プロ酵素型の分析方法。 - Google Patents
前立腺癌検出改善のための血清中前立腺特異抗原プロ酵素型の分析方法。 Download PDFInfo
- Publication number
- JP2006508332A JP2006508332A JP2004507519A JP2004507519A JP2006508332A JP 2006508332 A JP2006508332 A JP 2006508332A JP 2004507519 A JP2004507519 A JP 2004507519A JP 2004507519 A JP2004507519 A JP 2004507519A JP 2006508332 A JP2006508332 A JP 2006508332A
- Authority
- JP
- Japan
- Prior art keywords
- ppsa
- psa
- cancer
- total
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract description 43
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 title claims description 37
- 210000002966 serum Anatomy 0.000 title claims description 36
- 238000001514 detection method Methods 0.000 title claims description 23
- 108010072866 Prostate-Specific Antigen Proteins 0.000 title description 186
- 102000010911 Enzyme Precursors Human genes 0.000 title 1
- 108010062466 Enzyme Precursors Proteins 0.000 title 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 79
- 201000011510 cancer Diseases 0.000 claims abstract description 64
- 239000000523 sample Substances 0.000 claims abstract description 31
- 201000010099 disease Diseases 0.000 claims abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- 239000012472 biological sample Substances 0.000 claims abstract description 7
- 238000003745 diagnosis Methods 0.000 claims abstract description 5
- 239000013068 control sample Substances 0.000 claims abstract description 4
- 210000002307 prostate Anatomy 0.000 claims description 3
- 238000003556 assay Methods 0.000 abstract description 17
- 102100038358 Prostate-specific antigen Human genes 0.000 description 185
- 238000004458 analytical method Methods 0.000 description 23
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 19
- 238000003018 immunoassay Methods 0.000 description 18
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 108010029485 Protein Isoforms Proteins 0.000 description 8
- 102000001708 Protein Isoforms Human genes 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 238000001574 biopsy Methods 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000027455 binding Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010091628 alpha 1-Antichymotrypsin Proteins 0.000 description 2
- 239000003541 chymotrypsin inhibitor Substances 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 238000013211 curve analysis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 108060003552 hemocyanin Proteins 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- QGBNWHBKVFAIJY-JTQLQIEISA-N (2S)-2-acetamido-4-methylsulfanyl-N-(3-methylsulfanylpropyl)butanamide Chemical compound CSCCCNC(=O)[C@H](CCSC)NC(C)=O QGBNWHBKVFAIJY-JTQLQIEISA-N 0.000 description 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 102100039341 Atrial natriuretic peptide receptor 2 Human genes 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000961040 Homo sapiens Atrial natriuretic peptide receptor 2 Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102100038356 Kallikrein-2 Human genes 0.000 description 1
- 101710176220 Kallikrein-2 Proteins 0.000 description 1
- 101710159910 Movement protein Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000013198 immunometric assay Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/154,715 US20030219840A1 (en) | 2002-05-24 | 2002-05-24 | Method of analyzing proenzyme forms of prostate specific antigen in serum to improve prostate cancer detection |
| PCT/US2003/016148 WO2003100079A2 (en) | 2002-05-24 | 2003-05-22 | Method of analyzing proenzyme forms of prostate specific antigen in serum to improve prostate cancer detection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006508332A true JP2006508332A (ja) | 2006-03-09 |
| JP2006508332A5 JP2006508332A5 (enExample) | 2006-05-18 |
Family
ID=29548943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004507519A Pending JP2006508332A (ja) | 2002-05-24 | 2003-05-22 | 前立腺癌検出改善のための血清中前立腺特異抗原プロ酵素型の分析方法。 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20030219840A1 (enExample) |
| EP (1) | EP1506401A4 (enExample) |
| JP (1) | JP2006508332A (enExample) |
| CN (1) | CN1656379A (enExample) |
| WO (1) | WO2003100079A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090233313A1 (en) * | 2008-03-11 | 2009-09-17 | Axela Inc. | Quantification and affinity characterization of antibodies for the diagnosis of disease using optical diffraction |
| CN103134929A (zh) * | 2011-12-02 | 2013-06-05 | 沃克(天津)生物科技有限公司 | 游离前列腺特异抗原与总前列腺特异抗原一体化酶联免疫检测试剂盒及检测方法 |
| CN102520161A (zh) * | 2012-01-05 | 2012-06-27 | 中南大学 | 一种用于spr双通道法检测前列腺特异性抗原的生物传感芯片、试剂盒，检测方法 |
| CA2871877A1 (en) | 2012-05-16 | 2013-11-21 | Phadia Ab | Method for indicating the presence or non-presence of prostate cancer |
| BR112015011359B1 (pt) | 2012-11-20 | 2022-12-06 | Phadia Ab | Método baseado em uma combinação redundantemente designada de dados para indicar uma presença ou não presença de câncer de próstata agressivo (pca) em um indivíduo, dispositivo de ensaio e kit de teste |
| CN104007256A (zh) * | 2013-02-21 | 2014-08-27 | 林斯 | 总psa和游离psa二合一化学发光免疫诊断试剂盒的制备方法 |
| AU2015230017B2 (en) | 2014-03-11 | 2021-06-17 | A3P Biomedical Ab | Method for detecting a solid tumor cancer |
| CN105929151A (zh) * | 2016-06-30 | 2016-09-07 | 深圳市亚辉龙生物科技股份有限公司 | 前列腺特异性抗原同源异构体化学发光免疫检测试剂盒及其制备方法 |
| CN110382718A (zh) | 2017-02-01 | 2019-10-25 | 法迪亚股份有限公司 | 用于指示具有特定特征的个体中的前列腺癌的存在或不存在的方法 |
| CN111596060A (zh) * | 2020-05-19 | 2020-08-28 | 迪瑞医疗科技股份有限公司 | 前列腺特异性抗原同源异构体化学发光免疫检测试剂盒及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7659073B2 (en) * | 1997-04-30 | 2010-02-09 | Hybritech Incorporated | Forms of prostate specific antigens and methods for their detection |
| WO1998049323A1 (en) * | 1997-04-30 | 1998-11-05 | Hybritech Incorporated | Forms of prostate specific antigen and methods for their detection |
| US7211397B2 (en) * | 1999-04-30 | 2007-05-01 | Beckman Coulter, Inc. | Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection |
| US20040214246A1 (en) * | 2000-05-24 | 2004-10-28 | Wolfgang Hoesel | Antibodies against particular forms of propsa and use thereof in immunoassays |
-
2002
- 2002-05-24 US US10/154,715 patent/US20030219840A1/en not_active Abandoned
-
2003
- 2003-05-22 CN CNA038119021A patent/CN1656379A/zh active Pending
- 2003-05-22 EP EP03755428A patent/EP1506401A4/en not_active Withdrawn
- 2003-05-22 WO PCT/US2003/016148 patent/WO2003100079A2/en not_active Ceased
- 2003-05-22 JP JP2004507519A patent/JP2006508332A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003100079A2 (en) | 2003-12-04 |
| EP1506401A2 (en) | 2005-02-16 |
| CN1656379A (zh) | 2005-08-17 |
| US20030219840A1 (en) | 2003-11-27 |
| WO2003100079A3 (en) | 2004-09-23 |
| EP1506401A4 (en) | 2006-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4274330B2 (ja) | ｃＰＳＡの測定方法 | |
| US20120022793A1 (en) | Biomarkers for the diagnosis of prostate cancer in a non-hypertensive population | |
| US7211397B2 (en) | Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection | |
| US20100151501A1 (en) | Forms of Prostate Specific Antigens and Methods for their Detection | |
| ESPANA et al. | Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples | |
| JP4847873B2 (ja) | 上皮起源の癌を診断および予後診断するための方法 | |
| US20070254317A1 (en) | Method for Detecting the Activatable Free Form of Psa and the Use Thereof for Diagnosing Benign Pathologies of the Prostate and Adenocarcinoma of the Prostate | |
| JP2006508332A (ja) | 前立腺癌検出改善のための血清中前立腺特異抗原プロ酵素型の分析方法。 | |
| CN101680898A (zh) | Timp-1作为结肠直肠癌标志的用途 | |
| US6140065A (en) | Methods for diagnosing benign prostatic diseases and prostatic adenocarcinoma using an algorithm | |
| JP2002506210A (ja) | 前立腺ガンの識別方法 | |
| US7288636B2 (en) | Forms of prostate specific antigens and methods for their detection | |
| JP2002538433A (ja) | 前立腺ガンの病期分類 | |
| WO2004099780A1 (en) | Immunoassays for the detection of urokinase receptor forms | |
| JP4451784B2 (ja) | 前立腺癌腫瘍マーカー | |
| US20060199230A1 (en) | Use of prostate specific antigen to predict drug response | |
| WO1997039351A1 (en) | Novel methods for the prediction and early detection of prostatic adenocarcinoma | |
| JP2002509237A (ja) | 前立腺特異抗原の検出方法 | |
| JPH11118804A (ja) | Ｐｓａ−ａｃｔの測定 | |
| JP6312141B2 (ja) | 前立腺がん検査用尿中バイオマーカー | |
| Schmitt et al. | BTA TRAK™-A USEFUL DIAGNOSTIC TOOL IN URINARY BLADDER CANCER? | |
| CA2852757A1 (en) | Predictive biomarkers for breast cancer | |
| US20050272102A1 (en) | Method for diagnosis of prostate cancer | |
| CA2498147A1 (en) | Methods for detecting prostate cancer | |
| WO1999061914A1 (en) | Immunoassay for quantitative determination of prostate specific antigen (psa) free and complexed with alpha1-antichymotrypsin or alpha1-protease inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060323 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060323 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081118 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090421 |